Financial Sense Advisors Inc. Invests $975,000 in Edwards Lifesciences Co. (NYSE:EW)

Financial Sense Advisors Inc. acquired a new stake in Edwards Lifesciences Co. (NYSE:EW) in the 1st quarter, HoldingsChannel reports. The institutional investor acquired 10,200 shares of the medical research company’s stock, valued at approximately $975,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Riverview Trust Co purchased a new stake in Edwards Lifesciences in the 1st quarter valued at $34,000. DSM Capital Partners LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth about $28,000. Turtle Creek Wealth Advisors LLC purchased a new position in Edwards Lifesciences during the fourth quarter worth about $34,000. Rise Advisors LLC boosted its holdings in Edwards Lifesciences by 125.0% in the 1st quarter. Rise Advisors LLC now owns 477 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 265 shares during the last quarter. Finally, Pingora Partners LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $38,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of research analyst reports. Evercore ISI lifted their target price on Edwards Lifesciences from $89.00 to $91.00 and gave the company an “in-line” rating in a research report on Tuesday. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Barclays upped their price objective on shares of Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a report on Tuesday, May 7th. Oppenheimer lifted their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, March 18th. Finally, The Goldman Sachs Group initiated coverage on Edwards Lifesciences in a research note on Thursday, May 30th. They set a “buy” rating and a $107.00 price target on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $95.18.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $91.09 on Thursday. The business has a 50-day simple moving average of $87.99 and a 200-day simple moving average of $85.56. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The company has a market cap of $54.89 billion, a PE ratio of 39.26, a P/E/G ratio of 3.34 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. On average, equities research analysts forecast that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other news, CEO Bernard J. Zovighian bought 580 shares of the business’s stock in a transaction dated Monday, May 6th. The shares were acquired at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the completion of the transaction, the chief executive officer now owns 3,268 shares of the company’s stock, valued at $280,198.32. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Edwards Lifesciences news, VP Daniel J. Lippis sold 857 shares of the stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $85.60, for a total transaction of $73,359.20. Following the completion of the sale, the vice president now directly owns 23,890 shares of the company’s stock, valued at approximately $2,044,984. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bernard J. Zovighian purchased 580 shares of the business’s stock in a transaction dated Monday, May 6th. The shares were bought at an average price of $85.74 per share, with a total value of $49,729.20. Following the purchase, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at $280,198.32. The disclosure for this purchase can be found here. In the last quarter, insiders sold 90,499 shares of company stock worth $7,866,511. 1.27% of the stock is currently owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.